Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 3, 2005, Pages 1340-1346

  Suri, Daesman ^a   Weiss, Roy E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; DEXAMETHASONE; HYDROCORTISONE; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CUSHING DISEASE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYDROCORTISONE URINE LEVEL; HYPOPHYSIS ADRENAL SYSTEM; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; BLOOD; CLINICAL TRIAL; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; MIDDLE AGED; SECRETION; TREATMENT FAILURE;

ADRENOCORTICOTROPIC HORMONE; ADULT; CIRCADIAN RHYTHM; FEMALE; HUMANS; HYDROCORTISONE; HYPOGLYCEMIC AGENTS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; PITUITARY ACTH HYPERSECRETION; PITUITARY-ADRENAL SYSTEM; PPAR GAMMA; THIAZOLIDINEDIONES; TREATMENT FAILURE;

EID: 15944386690     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1746     Document Type: Article

References (29)

1. Carpenter PC 1988 Diagnostic evaluation of Cushing's syndrome. Endocrinol Metab Clin North Am 17:445-472
2. Newell-Price J, Trainer P, Besser M, Grossman A 1998 The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 19:647-672
3. Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J 2001 Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab 86:117-123
4. Bochicchio D, Losa M, Buchfelder M 1995 Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. J Clin Endocrinol Metab 80:3114-3120
5. Pereira AM, van Aken MO, van Dulken H, Schutte PJ, Biermasz NR, Smit JW, Roelfsema F, Romijn JA 2003 Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing's disease. J Clin Endocrinol Metab 88:5858-5864
6. Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Sutton ML 1990 Long-term follow-up of low-dose external pituitary irradiation for Cushing's disease. Clin Endocrinol (Oxf) 33:445-455
7. Murayama M, Yasuda K, Minamori Y, Mercado-Asis LB, Yamakita N, Morita H, Miura K 1994 Long term follow-up of Cushing's disease treated with reserpine and pituitary irradiation followed by subtotal adrenalectomy. Tohoku J Exp Med 172:97-109
8. Orth DN, Liddle GW 1971 Results of treatment in 108 patients with Cushing's syndrome. N Engl J Med 285:243-247
9. Sharpe GF, Kendall-Taylor P, Prescott RW, Ross WM, Davison C, Watson MJ, Cook DB 1985 Pituitary function following megavoltage therapy for Cushing's disease: long term follow up. Clin Endocrinol (Oxf) 22:169-177
10. Estrada J, Boronat M, Mielgo M, Magallon R, Millan I, Diez S, Lucas T, Barcelo B 1997 The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med 336:172-177
11. Nieman LK 2002 Medical therapy of Cushing's disease. Pituitary 5:77-82
12. Heaney AP, Fernando M, Yong WH, Melmed S 2002 Functional PPARγ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 8:1281-1287
13. Heaney AP, Fernando M, Melmed S 2003 PPARγ receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 111:1381-1388
14. Zhu Y, Fernando M, Heaney AP PPARγ binds a putative PPRE in the POMC promoter. Program of the 86th Annual Meeting of The Endocrine Society, New Orleans, LA, 2004, p 122 (Abstract OR33-6)
15. Stumvoll M, Haring HU 2002 Glitazones: clinical effects and molecular mechanisms. Ann Med 34:217-224
16. Ito K, Shimada J, Kato D, Toda S, Takagi T, Naito Y, Yoshikawa T, Kitamura N 2004 Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-γ ligand, on lung ischemia-reperfusion injury in rats. Eur J Cardiothorac Surg 25:530-536
17. Margeli A, Kouraklis G, Theocharis S 2003 Peroxisome proliferator activated receptor-γ (PPARγ) ligands and angiogenesis. Angiogenesis 6:165-169
18. Theocharisa S, Margeli A, Kouraklis G 2003 Peroxisome proliferator activated receptor-γ ligands as potent antineoplastic agents. Curr Med Chem Anti-Canc Agents 3:239-251
19. Yang FG, Zhang ZW, Xin DQ, Shi CJ, Wu XQ, Liu WJ, Guo YL, Wu JP 2004 Peroxisome proliferator-activated receptor-γ ligand troglitazone induces apoptosis in renal cell carcinoma. Beijing Da Xue Xue Bao 36:173-176
20. Yanovski JA, Cutler Jr GB, Chrousos GP, Nieman LK 1993 Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA 269:2232-2238
21. Landolt AM, Valavanis A, Girard J, Eberle AN 1986 Corticotrophin- releasing factor-test used with bilateral simultaneous inferior petrosal sinus blood-sampling for the diagnosis of pituitary dependent Cushing's disease. Clin Endocrinol (Oxf) 25:687-696
22. Giraldi FP, Invitti C, Cavagnini F 2001 The corticotropin-releasing hormone test in the diagnosis of ACTH-dependent Cushing's syndrome: a reappraisal. Clin Endocrinol (Oxf) 54:601-607
23. Van Cauter E 1988 Estimating false positive and false negative errors in analyses of hormone pulsatility. Am J Physiol 254:E786-E794
24. Van Cauter E 1979 Method for characterization of 24-hour temporal variation of blood constituents. Am J Physiol 236:E255-E264
25. Chrousos GP, Schulte HM, Oldfield EH, Gold PW, Cutler Jr GB, Loriaux DL 1984 The corticotropin-releasing factor stimulation test. An aid in the evaluation of patients with Cushing's syndrome. N Engl J Med 310:622-626
26. Cannavo S, Ambrosi B, Chiodini I, Vigo T, Russo A, Milici C, Barbetta L, Dall'Asta C, Adda G, Arosio M 2004 Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-γ ligand, rosiglitazone, in Cushing's disease. J Endocrinol Invest 27:RC8-RC11
27. Alevizaki M, Philippou G, Zapanti L, Alevizaki CC, Anastasiou E, Mavrikakis M Significant improvement of recurrent pituitary-dependent Cushing's syndrome after administration of a PPARγ agonist. Program of the 86th Annual Meeting of The Endocrine Society, New Orleans, LA, 2004, p 418 (Abstract P2-453)
28. Ambrosi B, Arosio M, Dall'Asta C, Cannavo S, Libe R, Vigo T, Chiodini I, Epaminonda P, Trimarchi F, Beck-Peccoz P 2004 Effects of the chronic administration of the PPARγ receptor ligand, rosiglitazone, in Cushing's disease. Eur J Endocrinol 151:173-178
29. Sood V, Colleran K, Burge MR 2000 Thiazolidinediones: a comparative review of approved uses. Diabetes Technol Ther 2:429-440